Anthrax immune globulin human is an immunizing agent used for the treatment of inhalational anthrax in adult and pediatric patients in combination with antibacterial agents. It is derived from the plasma of humans immunized with BioThrax (adsorbed anthrax vaccine), which is then further purified.
- Mechanism
- Curator reviewed
Polyclonal anthrax immune globulin is a passive immunizing agent that neutralizes anthrax toxin by binding to Protective Antigen (PA) to prevent PA-mediated cellular entry of anthrax edema factor and lethal factor. It is administered in combination with appropriate antibiotic therapy as the immunoglobulin itself is not known to have direct antibacterial activity against anthrax bacteria, which otherwise may continue to grow and produce anthrax toxins.
- Primary indication
- Anthrax immune globulin is indicated for the treatment of inhalational anthrax in adult and pediatric patients in combination with appropriate antibacterial drugs.Curator reviewed · 1 structured indication
- First approval
- Canada, 2017 · United States, 2015
- Also known as
- Anthrax immune globulin (human) · Anthrax immunoglobulin (human) · Bacillus anthracis immune globulin human
- Brand names
Resolves to
What you can answer from here — as of September 17, 2026
Which drugs share a target with Anthrax immune globulin human, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account